JP2019516765A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516765A5
JP2019516765A5 JP2018561686A JP2018561686A JP2019516765A5 JP 2019516765 A5 JP2019516765 A5 JP 2019516765A5 JP 2018561686 A JP2018561686 A JP 2018561686A JP 2018561686 A JP2018561686 A JP 2018561686A JP 2019516765 A5 JP2019516765 A5 JP 2019516765A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
compound
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018561686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516765A (ja
JP7141108B2 (ja
Filing date
Publication date
Priority claimed from GBGB1609222.3A external-priority patent/GB201609222D0/en
Application filed filed Critical
Publication of JP2019516765A publication Critical patent/JP2019516765A/ja
Publication of JP2019516765A5 publication Critical patent/JP2019516765A5/ja
Application granted granted Critical
Publication of JP7141108B2 publication Critical patent/JP7141108B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018561686A 2016-05-25 2017-05-25 医薬製剤 Active JP7141108B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1609222.3 2016-05-25
GBGB1609222.3A GB201609222D0 (en) 2016-05-25 2016-05-25 Pharmaceutical formulation
PCT/GB2017/051494 WO2017203270A1 (en) 2016-05-25 2017-05-25 Pharmaceutical formulation

Publications (3)

Publication Number Publication Date
JP2019516765A JP2019516765A (ja) 2019-06-20
JP2019516765A5 true JP2019516765A5 (OSRAM) 2020-07-02
JP7141108B2 JP7141108B2 (ja) 2022-09-22

Family

ID=56369959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018561686A Active JP7141108B2 (ja) 2016-05-25 2017-05-25 医薬製剤

Country Status (25)

Country Link
US (2) US10973821B2 (OSRAM)
EP (1) EP3463365B1 (OSRAM)
JP (1) JP7141108B2 (OSRAM)
KR (1) KR102464150B1 (OSRAM)
CN (1) CN109982704B (OSRAM)
AU (1) AU2017270942B2 (OSRAM)
CA (1) CA3024771A1 (OSRAM)
CY (1) CY1124733T1 (OSRAM)
DK (1) DK3463365T3 (OSRAM)
ES (1) ES2888951T3 (OSRAM)
GB (1) GB201609222D0 (OSRAM)
HR (1) HRP20211795T1 (OSRAM)
HU (1) HUE056129T2 (OSRAM)
IL (1) IL263167B (OSRAM)
LT (1) LT3463365T (OSRAM)
MA (1) MA45126A (OSRAM)
MX (1) MX382199B (OSRAM)
MY (1) MY197663A (OSRAM)
PL (1) PL3463365T3 (OSRAM)
PT (1) PT3463365T (OSRAM)
RU (1) RU2760681C2 (OSRAM)
SG (1) SG11201810323RA (OSRAM)
SI (1) SI3463365T1 (OSRAM)
WO (1) WO2017203270A1 (OSRAM)
ZA (1) ZA201807851B (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609222D0 (en) * 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
WO2021222045A1 (en) * 2020-04-26 2021-11-04 Apollomics Inc. Novel pharmaceutical formulation for c-met inhibitor
CN113429396A (zh) * 2021-06-08 2021-09-24 深圳市祥根生物医药有限公司 一种五元杂芳环衍生物及其制备方法和用途

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3202654A (en) 1962-04-27 1965-08-24 Bristol Myers Co 6-[alpha-hydroxy-and alpha-amino-alpha-pyrrolylacetamido] penicillanic acids and salts thereof
GB1051723A (OSRAM) 1962-04-27
US3252970A (en) 1963-02-27 1966-05-24 Ciba Geigy Corp Aromatization
BE631632A (OSRAM) 1963-04-26
US3268558A (en) 1964-11-05 1966-08-23 Ortho Pharma Corp 1-r-2, 4-dinitropyrroles
US3458515A (en) 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
GB1208014A (en) 1967-03-23 1970-10-07 Glaxo Lab Ltd Cephalosporins
US3573294A (en) 1968-03-14 1971-03-30 Glaxo Lab Ltd 7 - (arylglyoxamido)cephalosporanic acids and their salts and alpha-carbonyl derivatives
BE790747A (fr) 1971-10-30 1973-02-15 Whitefin Holding Sa Stereo-isomeres du 1-(1'-(0-chloro-benzyl)-pyrrol-2'-yl) -2-dibutyl sec.-amino-ethanol et procede pour leur preparation
GB1476503A (en) 1973-06-21 1977-06-16 Sterling Drug Inc 1-arylamino-and 1-arylimino-pyrroles and preparation thereof
BE848465A (fr) 1976-11-18 1977-03-16 Stereo-isomeres de 1-(1'-benzyl-2' pyrryl)-2-disec.butylaminoethanols a activite analgesique et preparations pharmaceutiques qui les contiennent
US4316900A (en) 1977-10-05 1982-02-23 Ciba-Geigy Corporation Piperazinopyrrolobenzodiazepines
JPS57142966A (en) 1981-02-27 1982-09-03 Sagami Chem Res Center (1-alkyl-2-pyrrolyl)glyoxylic acid amide derivative
JPS57144255A (en) 1981-03-03 1982-09-06 Sagami Chem Res Center Alpha-methylthio(1-alkyl-2-pyrrolyl)acetamide derivative
US4761424A (en) 1985-10-01 1988-08-02 Warner-Lambert Company Enolamides, pharmaceutical compositions and methods for treating inflammation
FR2601368B1 (fr) 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5637592A (en) 1994-07-12 1997-06-10 Janssen Pharmaceutica N.V. Acyl derivatives of azolones
ES2208685T3 (es) 1994-07-21 2004-06-16 Eli Lilly And Company Inhibidores de indolizina spla2.
EP0823423B1 (en) 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
EP0747756B1 (en) 1995-06-06 2000-05-24 Agfa-Gevaert N.V. Photographic materials
JPH09249669A (ja) 1996-03-13 1997-09-22 Ono Pharmaceut Co Ltd 縮合ピロール誘導体、およびそれらを有効成分として含有する薬剤
DE69819721T2 (de) 1997-06-13 2004-09-23 Cydex Inc., Overland Park Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
HUP0102923A3 (en) 1998-06-03 2002-01-28 Gpi Nil Holdings Inc Wilmingto Aza-heterocyclic compounds used to treat neurological disorders and hair loss and pharmaceutical compositions containing them
EP1027887B1 (en) 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
CA2372691C (en) 1999-05-04 2009-11-17 Janssen Pharmaceutica N.V. Antifungal ethers
WO2001008572A1 (de) 1999-07-30 2001-02-08 Norbert Heske Kanülenanordnung zum einbringen endoskopischer instrumente in einen menschlichen oder tierischen körper
EP1239835B1 (en) 1999-12-23 2013-03-20 Bend Research, Inc. Pharmaceutical compositions providing enhanced drug concentrations
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
US7202239B2 (en) 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
WO2002098876A1 (en) 2001-06-06 2002-12-12 Vertex Pharmaceuticals Incorporated Cak inhibitors and uses thereof
IL159438A0 (en) 2001-06-20 2004-06-01 Daiichi Seiyaku Co Diamine derivatives
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
WO2003063822A2 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
PL371593A1 (en) 2002-02-01 2005-06-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
EP1476163A4 (en) 2002-02-23 2009-05-27 Bristol Myers Squibb Co METHOD FOR TREATING HIV INFECTION BY PREVENTING INTERACTION OF CD4 AND GP120
JP2006500387A (ja) 2002-08-15 2006-01-05 雲清 劉 固形ナノ医薬およびその調製方法
US20050032871A1 (en) 2002-09-03 2005-02-10 Sugen, Inc. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
CA2517034A1 (en) 2003-03-13 2004-09-30 Synta Pharmaceuticals Corp. Fused pyrrole compounds
FR2854079B1 (fr) 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
WO2005040116A2 (en) 2003-10-24 2005-05-06 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
ATE409462T1 (de) 2004-05-28 2008-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
US20060058286A1 (en) 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
US7842810B2 (en) 2005-03-31 2010-11-30 Janssen Pharmaceutica, Nv Bicyclic pyrazole compounds as antibacterial agents
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
WO2006123145A1 (en) 2005-05-18 2006-11-23 F2G Ltd Antifungal agents
WO2007009083A2 (en) 2005-07-12 2007-01-18 Acadia Pharmaceuticals Inc. Compounds with activity at retinoic acid receptors
WO2007015866A2 (en) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
NZ571934A (en) 2006-03-20 2012-05-25 Vertex Pharma Methods of spray drying formulations of vx-950 (telaprevir)
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US20080118500A1 (en) 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
GB0623209D0 (en) 2006-11-21 2007-01-03 F2G Ltd Antifungal agents
JP5508859B2 (ja) 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
CN101260086B (zh) 2007-03-06 2011-08-10 中国科学院上海药物研究所 蛋白酪氨酸磷酸酯酶1b抑制剂及其制备方法和用途
GB0710121D0 (en) 2007-05-25 2007-07-04 F2G Ltd Antifungal agents
US20100215747A1 (en) 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
AU2009239778B2 (en) * 2008-04-24 2014-03-13 F2G Ltd Pyrrole antifungal agents
GB0809773D0 (en) 2008-05-29 2008-07-09 F2G Ltd Antifungal combination therapy
US20100093872A1 (en) 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
CA2760305A1 (en) 2009-04-28 2010-11-04 Boehringer Ingelheim International Gmbh Ex-vivo treatment of immunological disorders with pkc-theta inhibitors
US9040033B2 (en) 2010-06-14 2015-05-26 Dow Global Technologies Llc Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
WO2012060448A1 (ja) 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗真菌剤としての併用医薬組成物
CN102805733B (zh) 2011-06-01 2016-03-09 日东电工株式会社 颗粒制剂及其制造方法
SG11201401597TA (en) 2011-11-29 2014-05-29 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
KR20140146181A (ko) 2012-04-11 2014-12-24 다우 글로벌 테크놀로지스 엘엘씨 특정 치환체 분포를 갖는 에스테르화된 셀룰로즈 에테르
WO2014031422A1 (en) 2012-08-24 2014-02-27 Dow Global Technologies Llc Novel hydroxyalkyl methyl cellulose acetate succinates
CN104736572B (zh) 2012-08-24 2017-09-05 陶氏环球技术有限责任公司 部分交联的酯化纤维素醚
BR112015015758B1 (pt) 2013-01-22 2022-01-04 F. Hoffmann-La Roche Ag Dispersão sólida, formulação sólida de dose unitária, preparação farmacêutica e uso de uma dispersão sólida
DK3021832T3 (da) 2013-07-19 2021-05-25 Boehringer Ingelheim Vetmedica Gmbh Konserverede etherificerede cyclodextrinderivater indeholdende flydende vandig farmaceutisk sammensætning
WO2015007759A1 (en) 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
EP3076951B1 (en) 2013-12-05 2020-09-30 Celal Albayrak Process for the production of drug formulations for oral administration
PT107568B (pt) 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
MX2017006447A (es) 2014-11-21 2018-01-30 F2G Ltd Agentes antifungicos.
GB201609222D0 (en) * 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation

Similar Documents

Publication Publication Date Title
ES2390661T5 (es) Forma de presentación para administración por vía oral para éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico o sus sales
TWI540128B (zh) 醫藥組合物
CN1886120B (zh) 用于制备可口腔给药的固态药物组合物的方法
ES2988678T3 (es) Un comprimido que comprende un derivado de metoxiurea y partículas de manitol
CN106255496B (zh) 包括紫杉烷的无定形固体分散体、包括其的片剂以及用于制备其的方法
RU2489149C2 (ru) Стабилизированные аморфные формы иматиниба мезилата
JP2014523445A5 (OSRAM)
JP2019524883A5 (OSRAM)
JP2009530415A5 (OSRAM)
JP2019516765A5 (OSRAM)
JP2008533007A5 (OSRAM)
JP2014525449A5 (OSRAM)
RU2018142381A (ru) Фармацевтический препарат
JP2024544572A (ja) Rock2阻害剤のナノ結晶製剤およびその調製方法
CN101827584A (zh) N-芳基脲基药物的固态分散体产品
JP2018502118A (ja) 非晶質ヘミフマル酸テノホビルアラフェナミドおよびその予備混合物を調製するプロセス
KR101282847B1 (ko) 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
CN105358149A (zh) 粉防己碱家族的药物制剂和方法
CN101190912A (zh) 新的抗病毒化合物及其制备方法
KR102276281B1 (ko) 의약으로 사용하기 위한 펄린돌 광학이성질체의 약학적으로 허용가능한 염
CN107072954B (zh) 用于口服给药的包含洛贝格列酮的药物组合物
TWI558400B (zh) 苯基尿嘧啶化合物之調配物
CN104093400A (zh) 稳定的无定形雷特格韦钾盐预混料及其制备方法
JP2015189677A (ja) ソリフェナシン非晶質体を含有する医薬組成物
JP2016538312A (ja) 非晶質のコビシスタットの固体分散体